Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder (NCT01615367), a randomized phase 1, phase 2 study. The primary outcome is NEW Tx Scale.

2. Clinical Question

The study is relevant to an integrated-care question: whether a psychosocial treatment addressing nutrition, exercise, and wellness can be delivered to people with bipolar disorder and is acceptable to them. The registry’s rationale is that cardiovascular disease is a major source of morbidity and mortality in bipolar disorder and that psychosocial interventions for managing related risk factors had not been empirically validated. The study was designed to explore treatment feasibility and acceptability, with potential effects on cardiovascular risk factors, mood symptoms, and overall functioning also in view.

The posted primary result is not a direct comparison of cardiovascular risk or a clinical outcome. It is a score about perceptions of NEW Tx at the post-treatment visit. Interpretation therefore needs to distinguish the registry’s broad study aims from the narrower endpoint with numerical results. The TAU participants were not required to complete the questionnaire unless they chose to participate in NEW Tx following the waitlist period. That condition makes the TAU score a selected subset’s response, rather than a complete assessment of everyone assigned to TAU.

3. Trial Design

The registry record identifies NCT01615367 as a randomized, single-masked, parallel study in phase 1 and phase 2. Its listed status is completed. The record gives a study start date of 2012-05-21 and a primary completion date of 2017-02-28, with enrollment of 38. Massachusetts General Hospital is listed as the sponsor. These design details describe how the trial was registered; the registry record does not report who was masked or explain the masking procedures.

The intervention was NEW Tx, described as weekly individualized psychotherapy over 20 weeks. It brought together nutrition strategies, exercise interventions, and wellness treatment, along with strategies adapted for bipolar disorder. The TAU group met with a psychiatrist as often as clinically needed during the 20-week study period. The intervention description says TAU typically consists of at least one FDA-approved mood stabilizer. The arm descriptions state that 25 people would be randomized to each condition, while the registry’s overall enrollment is 38. The posted outcome counts vary by measure, so the arm descriptions should not be read as the number contributing to each result.

The study’s stated aims include feasibility and acceptability, and exploration of cardiovascular disease risk factors, mood symptoms, and functioning. The posted results include a Week 20 NEW Tx Scale and secondary measures at 20 weeks. The registry record does not report detailed recruitment procedures, eligibility criteria, the identity of the masked party, or an allocation-concealment method. Although randomization is listed, that fact alone does not supply those procedural details. Nor does it establish that every endpoint was analyzed according to original randomized assignment; the record does not provide analysis-population definitions.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Participants in the treatment as usual condition were not required to complete this assessment if they did not elect to complete the NEW Tx intervention following the waitlist period. Participants completed this survey at the post-treatment visit only. Results only includes data from participants who completed the treatment and had data to report.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as NEW Tx Scale, measured over 20 weeks.

The posted primary endpoint is the NEW Tx Scale at 20 weeks. It is a 10-item measure of participants’ expectations of NEW Tx and their acceptability of the treatment, with a comments section for unstructured feedback. Each item uses a 5-point Likert scale ranging from 1 (strongly agree) to 5 (strongly disagree). The item scores are summed to create a total score ranging from 10 to 50; higher scores indicate a poorer perception of treatment.

This endpoint is used to assess acceptability, an important question for an intervention intended to combine several behavioral strategies. It measures participants’ reported perceptions, not cardiovascular risk, mood symptoms, or functioning. Those domains appear in the study aims or secondary outcomes, but they are not what this score directly quantifies.

The interpretation of the arm means has an important qualification. TAU participants were not required to complete the scale if they did not elect to participate in NEW Tx after the waitlist period. The posted TAU result includes 4. Consequently, the mean for that group describes the participants who completed the measure under this conditional arrangement; it should not be treated as a complete measure of acceptability among all participants assigned to TAU. The registry record does not report additional details about the questionnaire’s administration or the handling of missing responses.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry reports continuous outcomes as means and standard deviations. A mean gives the average score among the participants contributing to that measure. The standard deviation describes how spread out individual scores are around that mean. It is not the uncertainty interval for the mean, and it does not describe the full range of scores. Means are useful summaries, but they can conceal variation in participants’ responses, especially in a small sample.

What does a mean difference describe?

For the secondary outcomes, the recalculated mean difference is the NEW Tx mean minus the TAU mean. A negative estimate therefore indicates a lower observed mean in NEW Tx; a positive estimate indicates a higher observed mean. Whether a higher score is favorable depends on the scale’s interpretation. The registry record explains the direction of the NEW Tx Scale, but it does not provide a direction-of-benefit interpretation for every secondary measure. A numerical sign alone should not be taken as a clinical conclusion.

The reported secondary comparisons are recalculated from posted summary statistics. They are unadjusted: they do not incorporate adjustment for other measured characteristics. The registry record does not report sponsor analyses for these secondary measures. These recalculations are useful for describing the observed summaries and their uncertainty, but they should not be mistaken for a prespecified analysis reported by the study sponsor.

How should the intervals be read?

An interval estimate describes a range of values compatible with the data under the method used. A narrower interval indicates more precision than a wider interval. When an interval for a difference spans zero, the data do not sharply distinguish a positive difference from a negative one. That does not prove there is no difference, and it does not establish that the interventions are equivalent. The registry record does not identify the confidence level or provide enough detail to evaluate all assumptions behind the recalculated intervals; they should be read as the posted recalculation’s uncertainty bounds, not as a sponsor-reported interval.

What does a p-value add?

A p-value describes how unusual data at least as extreme as those observed would be under a specified null model. It is not the probability that the null hypothesis is true, and it does not measure the size or practical importance of a difference. The secondary p-values are explicitly unadjusted. Their interpretation should account for the fact that several outcomes are being considered and that the record does not report a multiplicity strategy. The registry record also does not describe a prespecified statistical analysis plan, so it is not possible to verify which analyses were planned before the results were seen.

Why do outcome counts matter?

The number contributing to a mean is the outcome-specific count, not necessarily the number enrolled or assigned to an arm. Counts differ across the posted results. In particular, the NEW Tx Scale has 13 results for NEW Tx and 4 for TAU, while secondary outcomes have their own posted counts. The registry record does not report how missing observations were handled, why particular results were absent, or whether analyses followed intention-to-treat principles. For the primary scale, TAU completion was conditional on choosing to take part in NEW Tx after the waitlist period. This makes selection into measurement a central interpretive issue, beyond ordinary uncertainty from a small count.

What do the planning illustrations mean?

The planning illustrations use observed secondary effects as inputs to hypothetical sample-size calculations. The stated assumptions are a two-sided significance level of 0.05, equal allocation between arms, a normal approximation, and an effect to detect equal to a stated fraction of the observed effect. For example, planning for 100% of the observed LIFE- Range of Impaired Functioning Tool effect gives 445 participants per arm for 80% power and 596 participants per arm for 90% power. Planning for 75% or 50% of that observed effect gives larger estimates. Comparable illustrations for the depression and mania measures are also reported.

These are planning illustrations, not the study’s original design calculations and not observed power. They do not show the probability that this completed study detected an effect. Because they are based on observed effects from a small study, they are sensitive to uncertainty in those estimates; a small observed effect can imply large hypothetical sample requirements under the stated assumptions. The registry record does not report the trial’s own sample-size justification. No primary-endpoint planning illustration is available because the record says the values needed for a two-arm comparison of that continuous endpoint were missing or not estimable.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("NEW Tx", "Treatment as Usual (TAU)")
n   <- c(13, 4)
m   <- c(23.54, 37.75)
sp  <- c(12.8, 8.66)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  NEW Tx  13  23.540  12.800  15.805  31.275
CARM  Treatment as Usual (TAU)  4  37.750  8.660  23.970  51.530

11. Multiplicity, Missing Data and Analysis Populations

The registry record does not report a statistical analysis plan, a multiplicity adjustment, or a hierarchy of outcomes for interpreting several tests. It lists multiple secondary outcomes and includes unadjusted recalculated p-values for some of them. Without a reported plan, it is not clear which outcomes were intended as confirmatory, how the study would handle repeated testing, or whether any analyses were selected after results were examined. Unadjusted p-values should therefore be interpreted cautiously and should not be treated as a collection of independent confirmations.

Missing-data methods are also not reported in the registry record. It does not describe imputation, likelihood-based methods, complete-case rules, or sensitivity analyses. Nor does it explain the reasons that outcome counts differ. Consequently, the effect of missing observations on the estimates cannot be assessed from the record alone. The posted means describe participants with reported results; they do not automatically represent everyone randomized or enrolled.

The primary endpoint has a particularly important measurement condition: TAU participants were not required to complete the NEW Tx questionnaire if they did not elect to participate in NEW Tx after the waitlist period. The posted TAU result is based on 4, compared with 13 for NEW Tx. Selection into questionnaire completion may affect how comparable the observed means are. The record does not report whether non-completers differed from respondents or how this conditional completion was handled analytically.

The registry identifies randomization but does not report analysis populations, such as whether the primary analysis followed randomized assignment, included only participants who completed treatment, or used another definition. It also does not report adherence, treatment exposure, or the handling of protocol deviations. Without these details, the degree to which the posted results preserve the advantages of randomization cannot be determined. These absences do not invalidate the descriptive summaries, but they constrain causal and confirmatory interpretation.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent non-serious adverse event terms

The adverse-event record lists 19 participants at risk in each arm. It records 0 serious adverse events in NEW Tx and 0 in TAU, with 0 deaths in each group. Other adverse events are recorded for 5 participants in NEW Tx and 3 in TAU. These are the figures reported in the registry record; they should be read as event counts within the recorded groups, not as estimates of comparative risk.

The record does not list serious adverse-event terms, and it does not provide event descriptions or additional detail about severity, timing, or relatedness. The absence of a recorded serious event in these data does not demonstrate that serious events cannot occur, nor does it establish a safety difference between the conditions. Counts of other adverse events likewise do not show whether events were caused by treatment. Interpreting safety comparatively requires information about definitions, ascertainment, follow-up, and analysis that is not reported in the registry record.

These safety figures also answer a different question from the acceptability endpoint. Adverse-event counts concern reported events, while the NEW Tx Scale concerns treatment perceptions. Neither result should be substituted for the other when describing the study.

13. What the Result Does, and Does Not, Mean

The posted primary result describes treatment perceptions among participants who completed the NEW Tx Scale at the post-treatment visit. The NEW Tx group’s mean was 23.54 and the TAU group’s mean was 37.75; higher scores on this scale indicate poorer perceptions. The result is therefore a descriptive contrast in the observed questionnaire scores. It is not a direct estimate of change in cardiovascular risk, nor does it establish that NEW Tx improved participants’ health or functioning.

The primary record does not report a formal two-arm comparison because values were missing or not estimable for that continuous endpoint. The TAU questionnaire was optional for participants who did not choose to participate in NEW Tx after the waitlist period, and only 4 TAU results are posted. This makes it difficult to interpret the means as a comparison of the randomized groups as a whole. A difference in observed means could reflect differences between respondents, as well as any difference associated with treatment assignment.

The secondary recalculations add exploratory information about functioning and mood, but their wide intervals leave substantial uncertainty. Their unadjusted p-values do not establish definitive findings, and a result that does not distinguish an effect from zero does not prove equivalence or no effect. The registry record also lacks reported sponsor analyses, a multiplicity plan, missing-data methods, and analysis-population definitions, all of which matter when judging the strength of an inference.

The trial’s broad aims include feasibility, acceptability, cardiovascular risk factors, mood symptoms, and functioning. The specific posted primary measure addresses perceptions and acceptability, while the numerical secondary results concern selected functioning and mood outcomes. The record does not provide numerical primary results for waist circumference, despite its mention in the brief summary’s hypotheses. The results therefore address only part of the study’s stated questions and should not be generalized to endpoints without posted outcome data.

14. Why This Trial Matters Statistically

This study illustrates why the endpoint actually reported matters as much as the intervention’s broad rationale. The registry describes NEW Tx as an integrated approach to nutrition, exercise, and wellness for people with bipolar disorder, and identifies cardiovascular risk as an important motivation. Yet the posted primary numerical result is a treatment-perception scale, not a cardiovascular outcome. A reader must distinguish the motivation and hypotheses from the evidence attached to a particular endpoint.

It also shows how outcome-specific participation can complicate the apparent simplicity of a randomized comparison. Random assignment is listed, but the primary questionnaire was optional for TAU participants who did not elect to take part in NEW Tx following the waitlist period. Thus, the posted group means do not represent equally complete measurement of all assigned participants. The study’s randomized design remains relevant, but the conditional measurement process limits what can be inferred from this particular endpoint.

Finally, this record demonstrates why uncertainty and analysis reporting should accompany point estimates. Secondary mean differences are paired with broad intervals and unadjusted p-values, while the registry does not report a multiplicity strategy, missing-data methods, or sponsor analyses. The planning illustrations are based on observed effects and specified assumptions, not on the study’s original design or observed power. Those distinctions are essential for avoiding overly strong conclusions from exploratory results. The record is most informative when read as a small study with a feasibility and acceptability focus, limited posted outcome information, and unresolved uncertainty about comparative effects.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several trial-specific limitations restrict interpretation. The primary endpoint measures expectations and acceptability rather than a clinical or cardiovascular outcome. Although the brief summary identifies waist circumference among the study’s primary hypotheses, the posted primary measure is the NEW Tx Scale, and no numerical waist-circumference result is included in the detailed outcomes. The registry record does not explain this difference between the stated hypotheses and the posted endpoint.

Questionnaire completion in TAU was conditional on electing to participate in NEW Tx following the waitlist period. The primary result therefore has a small TAU measurement count and may reflect a selected subset. The registry record does not report how non-completion was handled or whether respondents differed from those without results. Detailed outcome counts also vary, and the record does not explain these differences.

For secondary outcomes, the available comparisons are recalculations from posted summary statistics rather than sponsor-reported analyses. Their intervals are broad, and the p-values are unadjusted. The record does not report a statistical analysis plan, multiplicity handling, analysis populations, missing-data methods, or sensitivity analyses. It also does not provide numerical results for every listed secondary outcome. These omissions make it difficult to assess how the posted findings relate to prespecified analyses or how robust they are to analytical choices.

The arm descriptions state planned assignments of 25 people per condition, while the registry lists enrollment of 38. The record does not explain the relation between these entries, nor does it report recruitment flow or adherence. It identifies a single-masked design but does not state who was masked. These gaps do not change the descriptive results, but they leave important aspects of trial conduct and analysis unreported.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder — NCT01615367.
• Registry record last updated 2018-06-07; status last verified 2018-05.
• Results first posted 2018-04-27.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01615367 is a completed, randomized, single-masked, parallel phase 1 and phase 2 study sponsored by Massachusetts General Hospital. The registry lists bipolar disorder as the condition, enrollment of 38, a start date of 2012-05-21, and a primary completion date of 2017-02-28. NEW Tx was described as weekly individualized psychotherapy over 20 weeks; TAU involved psychiatric visits as clinically needed.

The posted primary outcome is the NEW Tx Scale at 20 weeks, measuring treatment expectations and acceptability. The group means are descriptive, and the registry indicates that a two-arm comparison was not estimable. TAU completion was optional under a waitlist-related condition. Secondary recalculations cover functioning and mood, with broad intervals and unadjusted p-values. The registry record does not report multiplicity or missing-data methods, analysis populations, or sponsor analyses for those secondary outcomes.